CA2283472A1 - Procede permettant d'antagoniser le domaine humain src sh2 - Google Patents

Procede permettant d'antagoniser le domaine humain src sh2 Download PDF

Info

Publication number
CA2283472A1
CA2283472A1 CA002283472A CA2283472A CA2283472A1 CA 2283472 A1 CA2283472 A1 CA 2283472A1 CA 002283472 A CA002283472 A CA 002283472A CA 2283472 A CA2283472 A CA 2283472A CA 2283472 A1 CA2283472 A1 CA 2283472A1
Authority
CA
Canada
Prior art keywords
glu
domain
src
peptidomimetic
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002283472A
Other languages
English (en)
Inventor
Dennis A. Holt
Daniel F. Veber
Dennis S. Yamashita
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2283472A1 publication Critical patent/CA2283472A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne une méthode de traitement d'une maladie de résorption osseuse chez un patient, cette méthode consistant à administrer au sujet une dose thérapeutique efficace d'un composé qui forme une fixation ou une liaison covalente avec cys 185 du domaine src SH2. Les composés préférés pour une utilisation dans ladite méthode sont les composés de l'invention qui sont représentés par la formule (I) ou bien leur sel, hydrate ou solvate pharmaceutiquement acceptables. Dans la formule, X représente OR'', SR'', NR'', R'''; R'' représente H, méthyle, alkyle; R''' représente CONH¿2?, CONHMe, CO NHalkyle, SONH¿2?, SONHMe, SONH alkyle, SO¿2?NH¿2?, SO¿2?NHMe, SO¿2?NH alkyle; n représente 0,1 ou 2; R représente H, CH¿2?CH(NHCOR'''')CONHR'''''; une fraction organique; R'''' représente glu-glu-ileu-glu-NH¿2?, peptide, peptidomimétique, alkyle, alkyle substitué, aryle, aryle substitué, hétéroaryle, hétéroaryle substitué; R' représente H, peptidomimétique; ou R, R' représentent un système d'anneau fusionné substitué par H ou peptidomimétique. Cette invention concerne également une composition pharmaceutique contenant un excipient pharmaceutique approprié et un composé de formule (I).
CA002283472A 1997-03-10 1998-03-10 Procede permettant d'antagoniser le domaine humain src sh2 Abandoned CA2283472A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4065897P 1997-03-10 1997-03-10
US60/040,658 1997-03-10
PCT/US1998/004699 WO1998040093A1 (fr) 1997-03-10 1998-03-10 Procede permettant d'antagoniser le domaine humain src sh2

Publications (1)

Publication Number Publication Date
CA2283472A1 true CA2283472A1 (fr) 1998-09-17

Family

ID=21912217

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002283472A Abandoned CA2283472A1 (fr) 1997-03-10 1998-03-10 Procede permettant d'antagoniser le domaine humain src sh2

Country Status (4)

Country Link
EP (1) EP1007076A4 (fr)
JP (1) JP2001514662A (fr)
CA (1) CA2283472A1 (fr)
WO (1) WO1998040093A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2309792A1 (fr) 1997-11-12 1999-05-20 William C. Shakespeare Nouveaux inhibiteurs de transduction de signal, compositions les contenant

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580979A (en) * 1994-03-15 1996-12-03 Trustees Of Tufts University Phosphotyrosine peptidomimetics for inhibiting SH2 domain interactions
AU4440496A (en) * 1995-02-10 1996-08-22 Smithkline Beecham Corporation Use of src SH2 specific compounds to treat a bone resorption disease

Also Published As

Publication number Publication date
WO1998040093A1 (fr) 1998-09-17
JP2001514662A (ja) 2001-09-11
EP1007076A4 (fr) 2004-10-27
EP1007076A1 (fr) 2000-06-14

Similar Documents

Publication Publication Date Title
EA001220B1 (ru) Пептид или пептидомиметик, который связывается с рецептором тромбоэтина, фармацевтическая композиция и способ лечения
Panchamoorthy et al. Physical and functional interactions between SH2 and SH3 domains of the Src family protein tyrosine kinase p59fyn
US6280964B1 (en) Binding sites for phosphotyrosine binding domains
JP2009502983A (ja) タンパク質キナーゼｃイソフォームの抑制剤およびその使用
US11576946B2 (en) Peptidyl inhibitors of calcineurin-NFAT interaction
CA3078504A1 (fr) Inhibiteurs peptidiques bicycliques
EP0772773B1 (fr) PEPTIDES SE FIXANT AUX SH3 DE Src ET LEURS METHODES D'ISOLEMENT ET D'UTILISATION
WO1997007131A1 (fr) Oligopeptides acyles divers
AU2002355204A1 (en) Protein kinase inhibitors comprising ATP mimetics conjugated to peptides or peptidomimetics
EP1416934A2 (fr) Inhibiteurs de proteine kinase comprenant des mimetiques de atp conjugues a des peptides ou a des peptidomimetiques
JPH0987200A (ja) 骨吸収疾患を治療するためのｓｒｃ ｓｈ２特異的化合物の使用
WO1997002023A1 (fr) UTILISATION DE COMPOSES SPECIFIQUES DU DOMAINE Stat 6 SH2 POUR LE TRAITEMENT DES REACTIONS ALLERGIQUES
CA2283472A1 (fr) Procede permettant d'antagoniser le domaine humain src sh2
US20030096760A1 (en) Method of antagonizing the human SRC SH2 domain
WO1997002024A1 (fr) Utilisation de composes se liant specifiquement au domaine stat 5 sh2 pour augmenter l'erythropoiese
US6303574B1 (en) Scr SH3 binding peptides and methods of isolating and using same
JPH092974A (ja) 血球増生を促進するためのｈｃｐ ｓｈ２特異的化合物の使用
US10905769B2 (en) Peptide and peptide mimetic binding antagonists of polo-like kinase 1 polo box domain and methods of use
US7045617B2 (en) Bisbubstrate inhibitors of kinases
JP2004516301A (ja) 癌治療のためのｅ２ｆ−１／サイクリン相互作用の阻害剤
WO2005117932A1 (fr) Inhibiteurs du substrat de src tyrosine kinases tenant lieu d'agents therapeutiques agents
JP4332618B2 (ja) 抗ｈｉｖ剤
Marastoni et al. HIV protease inhibitors: synthesis and activity of N-aryl-N′-hydroxyalkyl hydrazide pseudopeptides
KR19980702115A (ko) 자기면역 질환 및 동종이식 거부 치료를 위한 ｌｃｋ ｓｈ２ 특이성 화합물의 용도
US20110034670A1 (en) Bisubstrate inhibitors of protein kinases as therapeutic agents

Legal Events

Date Code Title Description
FZDC Correction of dead application (reinstatement)
FZDE Dead